Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
133
days
Cost-effectiveness of abbreviated breast MRI and contrast-enhanced mammography for women with extremely dense breasts in a national breast cancer screening program: a micro-simulation study
AuthorsMengmeng Li; Marcel J.W. Greuter; Keris Poelhekken; Monique D. Dorrius; Karin M. Vermeulen; Antoinette D.I. van Asselt; Geertruida H. de Bock
AffiliationsDepartment of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Health Science, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
123
days
Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variability
AuthorsXiao Huang; Sarah Anderson; Valeria Dal Zotto; Shuko Harada; Andrea G Kahn; Meiling Zhou; Kui Zhang; Kanako Okamoto; Shi Wei
AffiliationsDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Mathematical Sciences, Michigan Technological University, Houghton, MI, USA; Department of Statistics, Grand Valley State University, Allendale, MI, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
55
days
End-of-life care values and treatment preferences among Japanese breast cancer patients and families: A dyadic cross-sectional study
AuthorsAkemi Hara; Ayu Ajitomi; Kazunoshin Tachibana; Kenji Gonda; Masahiro Wada; Rui Omori; Megumi Arai; Kayoko Konuma; Toyoaki Sawano; Yoshiaki Kanemoto; Hirotomo Miyatake; Tomohiro Kurokawa; Yukiko Kouchi; Norio Kanzaki; Yasuhiro Kotera; Yoshitake Takebayashi; Michio Murakami; Tohru Ohtake; Hiroaki Shimmura; Akihiko Ozaki
AffiliationsClinical Research Center, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, North Cartolina, USA; Breast and Thyroid Center, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Breast Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan; Department of Breast Surgery, Utsunomiya Central Clinic, Utsunomiya, Japan; Department of Breast Cancer, St. Luke's International Hospital, Tokyo, Japan; Department of Nursing, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Yushoukai Medical Corporation Nobishiroclinic, Fujisawa, Japan; Department of Urology, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; School of Health Sciences, Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom; Department of Health Risk Communication, Fukushima Medical University School of Medicine, Fukushima, Japan; Center for Infectious Disease Education and Research, The University of Osaka, Suita, Japan; EIPM Center, The University of Osaka, Suita, Japan
56
days
Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer — from feasibility to precision practice
AuthorsYueting Tan; Benyuan Cheng; Kun He; Xiaobing Xie
AffiliationsHunan University of Chinese Medicine, Changsha, Hunan, 410208, China; The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China
207
days
Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer
AuthorsDario Trapani; Sachin Kumar Deshmukh; Sharon Wu; Joanne Xiu; Priya Jayachandran; Shipra Gandhi; Nancy U. Lin; Giuseppe Curigliano; Philip M. Spanheimer; Daniel L. Abravanel; Milan Radovich; Maryam Lustberg; Stephanie L. Graff; George W. Sledge; Sara M. Tolaney; José P. Leone
AffiliationsMedical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Caris Life Sciences, Phoenix, AZ, USA; El Camino Hospital, Mountain View, CA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA; European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Yale School of Medicine, Yale University, New Haven, CT, USA; Lifespan Cancer Institute, Legorreta Cancer Center, Brown University, Providence, RI, USA
66
days
Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database
AuthorsJ.M. Hannoun-Levi; J. Gal; C. Weltens; V. Smanyko; D. Kauer-Domer; D. Pasquier; C. Lemanski; S. Racadot; G. Houvenaeghel; B. Guix; A. Belliere-Calandry; K. Loessl; B. Polat; C. Gutierrez; R. Galalae; C. Polgar; R. Schiappa; V. Strnad
AffiliationsDepartment of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d’Azur, Nice, France; University Côte d’Azur, Institut Hospitalo-Universitaire (IHU) RespirERA, 27 Rue du Professeur Delvalle, Nice, 06000, France; Department of Radiation Oncology, Radiation Oncology, University Hospital Gasthuisberg, Leuven, Belgium; Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria; Department of Radiation Oncology, Oscar Lambret Cancer Centre, Lille University, Lille, France; Department of Radiation Oncology, Montpellier Cancer Institute, Montpellier, France; Department of Radiation Oncology, Leon Berard Cancer Centre, Lyon, France; Department of Surgical Oncology, Paoli-Calmettes Cancer Institute, Marseille, France; Department of Radiation Oncology, Medical Institute for Radiotherapy & Oncology, Barcelona, Spain; Department of Radiation Oncology, Auvergne Jean Perrin Cancer Centre, Clermont-Ferrand, France; Department of Radiation Oncology, Radiation Oncology, Inselspital, Bern University Hospital, Switzerland; Department of Radiation Oncology, Wurzburg University, Wurzburg, Germany; Department of Radiation Oncology, Hospital del Mar, Brachytherapy Unite, Catalan Institute of Oncology, Barcelona, Spain; MedAustron Centre for Ion Therapy and Research, Wiener Neustadt, Austria; Radiotherapy Centre, National Institute of Oncology, Budapest, Hungary; Department of Radiotherapy, Semmelweis University, Budapest, Hungary; Department of Radiation Oncology, Erlangen University Hospital, Erlangen, Germany
307
days
The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors
AuthorsIlenia Migliaccio; Marta Paoli; Chiara Biagioni; Cristina Guarducci; Francesca Galardi; Giulia Anichini; Laura Biganzoli; Matteo Benelli; Luca Malorni
AffiliationsTranslational Research Unit, Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Italy; Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy; Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Italy; Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy
140
days
Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial
AuthorsFrédérique Penault-Llorca; Amelie Lusque; Thomas Filleron; Kevin Tran; Lili Du; Rick Baehner; Florence Dalenc; Magali Lacroix-Triki; Thomas Bachelot; Fabrice Andre; Pascal Boucher; Jérôme Lemonnier; W. Fraser Symmans
AffiliationsDepartment of Biopathology, Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, F-63000, France; Biostatistics & Health Data Science Unit, University of Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Exact Sciences, Madison, WI, USA; Department of Pathology, University of California, San Francisco, CA, USA; Department of Medical Oncology, Oncopole Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France; Department of Pathology, Institut Gustave Roussy, Villejuif, France; Department of Medical Oncology, Centre Leon Berard, Lyon, France; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Unicancer, Paris, France
103
days
PREDICT version 3.1 overestimates survival in older women with breast cancer: a population-based external validation
AuthorsJulia N. Wolbink; Leti van Bodegom-Vos; Luuk C.A. Ciere; Saskia le Cessie; Hein Putter; Anna Z. de Boer; Willeke van der Plas-Krijgsman; Frederiek van den Bos; Gerrit-Jan Liefers; Johanneke E.A. Portielje
AffiliationsDepartment of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands; Department of Gerontology and Geriatrics, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands; Department of Clinical Epidemiology, Leiden University Medical Centre, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands; Department of Oncology, Medical Center Haaglanden, P.O. Box 432, The Hague, 2501 CK, the Netherlands; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, the Netherlands
187
days
Diagnostic accuracy of intraoperative macroscopic margin evaluation in breast-conserving surgery
AuthorsC Florin Pop; Claudia Sanciu-Pop; Mathilde Lecomte; Etienne El-Helou; Michel Moreau; Guzel Dzhamalova; Brigitte Verheyden; Chirine Khaled; Denis Larsimont; Isabelle Veys; Gabriel Liberale
AffiliationsDepartment of Surgical Oncology, Institut Jules Bordet, The Brussels University Hospital (HUB), Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, CHU de Liege, Liege, Belgium; Data Centre and Statistics Department, Institut Jules Bordet, The Brussels University Hospital (HUB), Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, Institut Jules Bordet, The Brussels University Hospital (HUB), Université Libre de Bruxelles, Brussels, Belgium
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days